Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

NCT ID: NCT02389946

Last Updated: 2022-08-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 1334 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-05-31
• Study Completion Date: 2021-03-31

Brief Summary

The objective of this study is to assess the safety and efficacy of the Orsiro Sirolimus Eluting Coronary Stent System in the treatment of subjects with up to three native de novo or restenotic (standard PTCA only) coronary artery lesions compared to the Xience coronary stent system.

Detailed Description

The BIOTRONIK BIOFLOW-V clinical trial is a prospective, multicenter, randomized, controlled trial combining data on the randomized subjects with data from two historical studies by employing a Bayesian approach.

Subjects with CAD that qualify for PCI with stenting will be screened per the protocol inclusion and exclusion criteria to achieve a total of up to 1,400 randomized subjects. Eligible subjects will be randomized in a 2:1 ratio, stratified by study center, to undergo percutaneous coronary revascularization with either the Orsiro Sirolimus Eluting Stent System (treatment group) or the Xience Everolimus Eluting Stent System (control group).

Subjects may receive treatment of up to three target lesions, one or two target lesions per target vessel, for a maximum of two target vessels. The target lesion(s) must be de novo or restenotic lesion(s) of ≤ 36 mm in length in native coronary artery(ies), with a reference vessel diameter of 2.25-4.0 mm. Treatment of restenotic lesions is allowed provided that the target lesion was previously treated with PTCA only. All treatment with study stents is to be performed during a single index procedure. Note: Concurrent treatment of non-target lesions during the index procedure is not allowed.

Randomized subjects will have clinical follow-up at 1 month, 6 months, 12 months and at 2, 3, 4 and 5 years following the index procedure.

To assess the non-inferiority of the Orsiro stent compared to the Xience stent, BIOFLOW-V randomized subjects will be combined with historical subjects from the BIOFLOW-II and BIOFLOW-IV randomized trials employing a Bayesian approach. Only subjects who meet all clinical and angiographic eligibility criteria of the BIOFLOW-V trial will be included in the analysis.

Conditions

Coronary Artery Disease; Atherosclerosis, Coronary; Myocardial Ischemia; Ischemic Heart Disease; Acute Coronary Syndrome; Angina Pectoris

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Orsiro sirolimus coronary stent system

Intervention with a Orsiro DES.

Group Type: EXPERIMENTAL

Orsiro DES

Intervention Type: DEVICE

Orsiro is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform), and a drug product (a formulation of sirolimus) contained in a bioabsorbable polymer coating.

Xience everolimus coronary stent system

Intervention with a Xience DES.

Group Type: ACTIVE_COMPARATOR

Xience DES

Intervention Type: DEVICE

Interventions

Orsiro DES

Orsiro is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform), and a drug product (a formulation of sirolimus) contained in a bioabsorbable polymer coating.

Intervention Type: DEVICE

Xience DES

Intervention Type: DEVICE

Other Intervention Names

Orsiro sirolimus coronary stent system; Xience everolimus coronary stent system

Eligibility Criteria

Inclusion Criteria

1. Subject is ≥18 years or the minimum age required for legal adult consent in the country of enrollment.

2. Subject is an acceptable candidate for PCI.

3. Subject is an acceptable candidate for CABG.

4. Subject has clinical evidence of ischemic heart disease, stable or unstable angina pectoris or documented silent ischemia.

5. Subject is eligible for dual anti-platelet therapy treatment with aspirin plus either, clopidogrel, prasugrel, ticagrelor or ticlopidine.

6. Subject has provided written informed consent.

7. Subject is willing to comply with study follow-up requirements.

Each target lesion/vessel must meet all of the following angiographic criteria for the subject to be eligible for the trial:

1. Subject has up to three target lesions in up to two separate target vessels (two target lesions in one vessel and one target lesion in a separate vessel).

2. Target lesion must be de novo or restenotic lesion in native coronary artery; restenotic lesion must have been treated with a standard PTCA only.

3. Target lesion must be in major coronary artery or branch (target vessel).

4. Target lesion must have angiographic evidence of ≥ 50% and < 100% stenosis (by operator visual estimate). If the target lesion is < 70% stenosed, clinical evidence of ischemia by positive functional study, CT, electrocardiography, FFR, or post infarct angina.

5. TIMI flow > 1.

6. Target lesion must be ≤ 36 mm in length by operator visual estimate.

7. Target vessel RVD of 2.25-4.0 mm by operator visual estimate.

8. Target lesion must be treatable with a maximum of two overlapping stents.

Exclusion Criteria

1. Subject has clinical symptoms and/or electrocardiogram (ECG) changes consistent with acute ST elevation myocardial infarction (STEMI) within 72 hours prior to the index procedure. Hemodynamically stable non-STEMI (NSTEMI) subjects are eligible for study enrollment.

2. Subject is hemodynamically unstable.

3. Subject is pregnant and/or breastfeeding or intends to become pregnant during the duration of the study.

4. Subject has a known allergy to contrast medium that cannot be adequately pre-medicated, or any known allergy to thienopyridine, aspirin, both heparin and bivalirudin, L-605 cobalt-chromium (Co-Cr) alloy or one of its major elements (cobalt, chromium, tungsten and nickel), acrylic, fluoropolymers, silicon carbide, PLLA, sirolimus or everolimus.

5. Revascularization of any target vessel within 9 months prior to the index procedure or previous PCI of any non-target vessel within 30 days prior to the index procedure.

7. Planned surgery within 6 months of index procedure unless dual antiplatelet therapy can be maintained throughout the peri-surgical period.

8. History of a stroke or transient ischemic attack (TIA) within 6 months prior to the index procedure.

9. Subjects with active bleeding disorders, active coagulopathy, or any other reason, who are ineligible for DAPT.

10. Subject will refuse blood transfusions.

11. Subject has documented left ventricular ejection fraction (LVEF) < 30% within 90 days prior to the index procedure.

12. Subject is dialysis-dependent.

13. Subject has impaired renal function (i.e., blood creatinine > 2.5 mg/dL or 221 μmol/L determined within 7 days prior to the index procedure).

14. Subject has leukopenia (i.e. < 3,000 white blood cells/mm3), thrombocytopenia (i.e. < 100,000 platelets/mm3) or thrombocytosis (i.e. > 700,000 platelet/mm3).

15. Subject is receiving oral or intravenous immunosuppressive therapy (inhaled steroids are permitted), or has known life-limiting immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus; diabetes mellitus is permitted).

16. Subject is receiving chronic anticoagulation (e.g. coumadin, dabigatran, apixaban, rivaroxaban or any other agent).

17. Subject has life expectancy of < 1 year.

18. Subject is participating in another investigational (medical device or drug) clinical study. Subjects may be concurrently enrolled in a post-market study, as long as the post-market study device, drug or protocol does not interfere with the investigational treatment or protocol of this study.

19. In the investigator's opinion, subject will not be able to comply with the follow-up requirements.

Subjects will be excluded from the trial if any of the target lesions/vessels meets any of the following angiographic criteria:

1. Target lesion is located within a saphenous vein graft or arterial graft.

2. Target lesion is a restenotic lesion that was previously treated with a bare metal or drug eluting stent (in-stent restenosis).

3. Target lesion has any of the following characteristics:

1. Lesion location is within the left main coronary artery, or within 3 mm of the origin of the left anterior descending (LAD) or left circumflex (LCX).

2. Involves a side branch of > 2.0 mm in diameter. Note: Lesions within 3 mm of the origin of the right coronary artery may be treated.

4. Target vessel/lesion is excessively tortuous/angulated or is severely calcified, that would prevent complete inflation of an angioplasty balloon. This assessment should be based on visual estimation.

5. Target vessel has angiographic evidence of thrombus.

6. Target lesion is totally occluded (100% stenosis).

7. Target vessel was treated with brachytherapy any time prior to the index procedure.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Biotronik AG

INDUSTRY

Sponsor Role: collaborator

Baim Institute for Clinical Research

OTHER

Sponsor Role: collaborator

Medstar Health Research Institute

OTHER

Sponsor Role: collaborator

Biotronik, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ron Waksman, MD

Role: STUDY_CHAIR

Medstar Health Research Institute

David Kandzari, MD

Role: PRINCIPAL_INVESTIGATOR

Piedmont Heart Institute

Jacques Koolen, MD

Role: PRINCIPAL_INVESTIGATOR

Catharina Ziekenhuis

Locations

Fairhope, Alabama, United States

Concord, California, United States

La Mesa, California, United States

Laguna Hills, California, United States

Mission Viejo, California, United States

Washington D.C., District of Columbia, United States

Clearwater, Florida, United States

Hollywood, Florida, United States

Orlando, Florida, United States

Tampa, Florida, United States

Atlanta, Georgia, United States

Urbana, Illinois, United States

Fort Wayne, Indiana, United States

Baltimore, Maryland, United States

Boston, Massachusetts, United States

Bay City, Michigan, United States

Detroit, Michigan, United States

Lansing, Michigan, United States

Pontiac, Michigan, United States

Rochester, Michigan, United States

Troy, Michigan, United States

Ypsilanti, Michigan, United States

Minneapolis, Minnesota, United States

Omaha, Nebraska, United States

Hackensack, New Jersey, United States

Neptune City, New Jersey, United States

Newark, New Jersey, United States

New York, New York, United States

New York, New York, United States

New York, New York, United States

Asheville, North Carolina, United States

Greensboro, North Carolina, United States

Fargo, North Dakota, United States

Cincinnati, Ohio, United States

Cleveland, Ohio, United States

Columbus, Ohio, United States

Elyria, Ohio, United States

Toledo, Ohio, United States

Toledo, Ohio, United States

Portland, Oregon, United States

Butler, Pennsylvania, United States

Mechanicsburg, Pennsylvania, United States

Wynnewood, Pennsylvania, United States

York, Pennsylvania, United States

Providence, Rhode Island, United States

Greenville, South Carolina, United States

Rock Hill, South Carolina, United States

Knoxville, Tennessee, United States

Dallas, Texas, United States

Houston, Texas, United States

McKinney, Texas, United States

Tyler, Texas, United States

Charlottesville, Virginia, United States

Virginia Beach, Virginia, United States

Charleston, West Virginia, United States

Adelaide, , Australia

Genk, , Belgium

Leuven, , Belgium

Roeselare, , Belgium

Calgary, Alberta, Canada

Aarhus, , Denmark

Bad Segeberg, , Germany

Berlin, , Germany

Berlin, , Germany

Hamburg, , Germany

Minden, , Germany

Neuss, , Germany

Budapest, , Hungary

Pécs, , Hungary

Szeged, , Hungary

Haifa, , Israel

Jerusalem, , Israel

Petah Tikva, , Israel

Rehovot, , Israel

Tel Aviv, , Israel

Breda, , Netherlands

Eindhoven, , Netherlands

Nieuwegein, , Netherlands

Auckland, , New Zealand

Daegu, , South Korea

Gwangju, , South Korea

Seoul, , South Korea

Seoul, , South Korea

Seoul, , South Korea

Barcelona, , Spain

Barcelona, , Spain

Madrid, , Spain

Málaga, , Spain

Seville, , Spain

Lausanne, , Switzerland

Zurich, , Switzerland

Zurich, , Switzerland

Countries

United States; Australia; Belgium; Canada; Denmark; Germany; Hungary; Israel; Netherlands; New Zealand; South Korea; Spain; Switzerland

References

Doros G, Massaro JM, Kandzari DE, Waksman R, Koolen JJ, Cutlip DE, Mauri L. Rationale of a novel study design for the BIOFLOW V study, a prospective, randomized multicenter study to assess the safety and efficacy of the Orsiro sirolimus-eluting coronary stent system using a Bayesian approach. Am Heart J. 2017 Nov;193:35-45. doi: 10.1016/j.ahj.2017.08.001. Epub 2017 Aug 5.

Reference Type: BACKGROUND

PMID: 29129253 (View on PubMed)

Kandzari DE, Mauri L, Koolen JJ, Massaro JM, Doros G, Garcia-Garcia HM, Bennett J, Roguin A, Gharib EG, Cutlip DE, Waksman R; BIOFLOW V Investigators. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial. Lancet. 2017 Oct 21;390(10105):1843-1852. doi: 10.1016/S0140-6736(17)32249-3. Epub 2017 Aug 26.

Reference Type: RESULT

PMID: 28851504 (View on PubMed)

Kandzari DE, Koolen JJ, Doros G, Massaro JJ, Garcia-Garcia HM, Bennett J, Roguin A, Gharib EG, Cutlip DE, Waksman R; BIOFLOW V Investigators. Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin Durable Polymer Everolimus-Eluting Stents. J Am Coll Cardiol. 2018 Dec 25;72(25):3287-3297. doi: 10.1016/j.jacc.2018.09.019. Epub 2018 Sep 23.

Reference Type: RESULT

PMID: 30257191 (View on PubMed)

Roguin A, Kandzari DE, Marcusohn E, Koolen JJ, Doros G, Massaro JM, Garcia-Garcia HM, Bennett J, Gharib EG, Cutlip DE, Waksman R. Subgroup Analysis Comparing Ultrathin, Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin, Durable Polymer Everolimus-Eluting Stents in Acute Coronary Syndrome Patients. Circ Cardiovasc Interv. 2018 Oct;11(10):e007331. doi: 10.1161/CIRCINTERVENTIONS.118.007331.

Reference Type: RESULT

PMID: 30354631 (View on PubMed)

Mankerious N, Toelg R, Abdelghani M, Garcia-Garcia HM, Farhan S, Allali A, Windecker S, Lefevre T, Saito S, Kandzari DE, Waksman R, Richardt G, Hemetsberger R. Impact of coronary artery tortuosity on outcomes following stenting with newer-generation drug-eluting stents. An analysis of the randomized BIOFLOW trials. Rev Esp Cardiol (Engl Ed). 2025 Aug;78(8):682-691. doi: 10.1016/j.rec.2024.12.009. Epub 2025 Jan 4. English, Spanish.

Reference Type: DERIVED

PMID: 39761745 (View on PubMed)

Hemetsberger R, Mankerious N, Toelg R, Abdelghani M, Farhan S, Garcia-Garica HM, Allali A, Windecker S, Lefevre T, Saito S, Kandzari D, Waksman R, Richardt G. Patients with higher-atherothrombotic risk vs. lower-atherothrombotic risk undergoing coronary intervention with newer-generation drug-eluting stents: an analysis from the randomized BIOFLOW trials. Clin Res Cardiol. 2023 Sep;112(9):1278-1287. doi: 10.1007/s00392-023-02205-4. Epub 2023 Apr 16.

Reference Type: DERIVED

PMID: 37062047 (View on PubMed)

Hemetsberger R, Abdelghani M, Toelg R, Garcia-Garcia HM, Farhan S, Mankerious N, Elbasha K, Allali A, Windecker S, Lefevre T, Saito S, Kandzari D, Waksman R, Richardt G. Complex vs. non-complex percutaneous coronary intervention with newer-generation drug-eluting stents: an analysis from the randomized BIOFLOW trials. Clin Res Cardiol. 2022 Jul;111(7):795-805. doi: 10.1007/s00392-022-01994-4. Epub 2022 Feb 25.

Reference Type: DERIVED

PMID: 35212802 (View on PubMed)

Hemetsberger R, Abdelghani M, Toelg R, Mankerious N, Allali A, Garcia-Garcia HM, Windecker S, Lefevre T, Saito S, Slagboom T, Kandzari D, Koolen J, Waksman R, Richardt G. Impact of Coronary Calcification on Clinical Outcomes After Implantation of Newer-Generation Drug-Eluting Stents. J Am Heart Assoc. 2021 Jun 15;10(12):e019815. doi: 10.1161/JAHA.120.019815. Epub 2021 May 29.

Reference Type: DERIVED

PMID: 34056911 (View on PubMed)

Dan K, Garcia-Garcia HM, Kolm P, Windecker S, Saito S, Kandzari DE, Waksman R. Comparison of Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stents and Thin, Durable-Polymer Everolimus-Eluting Stents in Calcified or Small Vessel Lesions. Circ Cardiovasc Interv. 2020 Sep;13(9):e009189. doi: 10.1161/CIRCINTERVENTIONS.120.009189. Epub 2020 Sep 8.

Reference Type: DERIVED

PMID: 32895004 (View on PubMed)

Toelg R, Slagboom T, Waltenberger J, Lefevre T, Saito S, Kandzari DE, Koolen J, Richardt G. Individual patient data analysis of the BIOFLOW study program comparing safety and efficacy of a bioresorbable polymer sirolimus eluting stent to a durable polymer everolimus eluting stent. Catheter Cardiovasc Interv. 2021 Nov 1;98(5):848-856. doi: 10.1002/ccd.29254. Epub 2020 Sep 5.

Reference Type: DERIVED

PMID: 32890442 (View on PubMed)

Kandzari DE, Koolen JJ, Doros G, Garcia-Garcia HM, Bennett J, Roguin A, Gharib EG, Cutlip DE, Waksman R; BIOFLOW V Investigators. Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization: 3-Year Outcomes From the Randomized BIOFLOW V Trial. JACC Cardiovasc Interv. 2020 Jun 8;13(11):1343-1353. doi: 10.1016/j.jcin.2020.02.019.

Reference Type: DERIVED

PMID: 32499026 (View on PubMed)

Mattke S, Hanson M, Bentele M, Kandzari DE. Cost and Mortality Implications of Lower Event Rates After Implantation of an Ultrathin-Strut Coronary Stent Compared With a Thin-Strut Stent Over Four Years. Cardiovasc Revasc Med. 2020 Jul;21(7):835-842. doi: 10.1016/j.carrev.2019.12.018. Epub 2019 Dec 18.

Reference Type: DERIVED

PMID: 31954661 (View on PubMed)

Mattke S, Hanson M, Dallmann AC, Bentele M. Health Economic Evaluation of an Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Coronary Stent Compared to a Thin, Durable-Polymer Everolimus-Eluting Stent. Cardiovasc Revasc Med. 2019 Sep;20(9):752-757. doi: 10.1016/j.carrev.2018.11.006. Epub 2018 Nov 20.

Reference Type: DERIVED

PMID: 30638888 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

BIOFLOW-V

Identifier Type: -

Identifier Source: org_study_id